VTAK (Catheter Precision) ROCE %: -51.16% (As of Mar. 2026)

What is Catheter Precision ROCE %?

Catheter Precision VTAK +29.35% 28 ROCE % is -51.16% as of Mar. 2026. GuruFocus rates VTAK with a GF Score™ of 28/100 and a GF Value™ of $1.72 (Possible Value Trap). The stock has 7 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Catheter Precision's annualized ROCE % for the quarter that ended in Mar. 2026 was -51.16%.

Catheter Precision (AMEX:VTAK) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Catheter Precision ROCE % Related Terms

Catheter Precision ROCE % Historical Data

* Premium members only.

The historical data trend for Catheter Precision's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Catheter Precision ROCE % Chart

Catheter Precision Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

-141.62

-182.94

-376.14

-49.85

-102.55

Catheter Precision Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															-81.64	-121.85	-42.52	-149.03	-51.16

28GF Score

Catheter Precision Inc VTAK

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Catheter Precision ROCE % Calculation

Catheter Precision's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	-19.224	/	( ( (27.77 - 2.23)	+	(15.86 - 3.907) )	/ 2 )
	=	-19.224	/	( (25.54	+	11.953)	/ 2 )
	=	-19.224	/	18.7465
	=	-102.55 %

Catheter Precision's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	-6.984	/	( ( (15.86 - 3.907)	+	(35.085 - 19.738) )	/ 2 )
	=	-6.984	/	( ( 11.953	+	15.347 )	/ 2 )
	=	-6.984	/	13.65
	=	-51.16 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -51.16% mean?

Catheter Precision (VTAK) has a ROCE % of -51.16% as of Mar. 2026.

Is Catheter Precision's ROCE % too high?

Catheter Precision's current ROCE % is -51.16%. Overall, Catheter Precision has a GF Score™ of 28/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Catheter Precision's ROCE % compare to VYCO and BJDX?

Catheter Precision's ROCE % of -51.16% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Medical Devices & Instruments company?

The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Catheter Precision's current ROCE % is -51.16%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Catheter Precision stock overvalued right now?

Based on GuruFocus' analysis, Catheter Precision (VTAK) is currently considered Possible Value Trap. The stock's GF Value™ is $1.72, compared to a current price of $1.19 — trading 30.8% below its estimated fair value. The current ROCE % is -51.16%. Catheter Precision's overall GF Score™ is 28/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Catheter Precision (VTAK), the current ROCE % is -51.16% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Catheter Precision (VTAK) Overvalued in 2026?

Based on GuruFocus' analysis, Catheter Precision stock appears to be undervalued. The current stock price of $1.19 is trading 30.8% below its estimated GF Value™ of $1.72. GuruFocus considers Catheter Precision to be Possible Value Trap.

Key valuation signals for VTAK:

ROCE %: -51.16%
GF Value™: $1.72 vs. price of $1.19 (30.8% below fair value)
GF Score™: 28/100 with 7 warning signs

No single metric tells the full story. See the VTAK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Catheter Precision Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies VYCO BJDX NUWE ODYY IVF PFSA ESMC AEMD RMSL BTCY ABT SYK MDT BSX EW XTER:SHL DXCM GEHC SZSE:300760 XAMS:PHIA

Address 1670 Highway 160 West, Suite 205, Fort Mill, SC, USA, 29708

Website https://www.catheterprecision.com

Catheter Precision Inc is engaged in the design, manufacture, and sale of medical technologies focused in the field of cardiac electrophysiology, or EP. The company's two primary products include the VIVO System and LockeT. The VIVO System, which is an acronym for View into Ventricular Onset System(VIVO or VIVO System), is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. Its newest product, LockeT, is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure.

28GF Score

Get the complete analysis for VTAK

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.19

Price

$1.72

GF Value

View VTAK Analysis

See ROCE % data for all stocks →